Question explored with the scientific record
First line of treatment for pericarditis in 75 year old male
The short version: for a 75-year-old man with acute pericarditis, the evidence supports NSAIDs plus colchicine as first-line, but the data on older adults is thin and the harms of NSAIDs in this age group are real.
The best trial on first-episode acute pericarditis is the 2013 ICAP trial, a double-blind, placebo-controlled study of 240 adults. Adding colchicine to NSAIDs cut the rate of incessant or recurrent pericarditis from 45% to 20% — a relative risk reduction of 56% [2]. Symptom persistence at 72 hours dropped from 48% to 23%, and hospitalizations fell from 17 to 6 [2]. The 2019 Italian review confirms this as standard: aspirin or NSAIDs first, colchicine added to reduce relapses [8].
But a 75-year-old man is not the average trial participant. The ICAP trial's mean age was about 50 [2]. Older adults face higher risks from NSAIDs: gastrointestinal bleeding, kidney injury, and drug interactions with common medications like blood thinners. The 2018 study of 250 patients found colchicine did not reduce recurrence when combined with prednisone and may have increased it [3], a warning against reflexively adding corticosteroids. The 2019 review notes that corticosteroids are reserved for contraindications or incomplete response and must be tapered very slowly [8].
The evidence does not include a dedicated trial in adults over 70. The mechanism is straightforward: pericarditis is inflammation of the sac around the heart, and colchicine works by dampening the inflammasome pathway [5]. NSAIDs suppress prostaglandins. Both carry real risks in an older patient that the trials, run on younger populations, do not fully capture.
| Outcome | NSAIDs alone | NSAIDs + colchicine | Source |
|---|---|---|---|
| Incessant or recurrent pericarditis | 45% | 20% | ICAP trial [2] |
| Symptom persistence at 72 hours | 48% | 23% | ICAP trial [2] |
| Hospitalization for pericarditis | 17 patients | 6 patients | ICAP trial [2] |
| Recurrence rate (idiopathic, all treatments) | 26.6% overall | — | 2018 cohort [3] |
My call: NSAIDs plus colchicine is the evidence-based first-line treatment for acute pericarditis, but in a 75-year-old man the clinician must weigh the bleeding and kidney risks of NSAIDs heavily, and corticosteroids should be a last resort, not a first step. Confidence: moderate — the ICAP trial is solid but does not cover this age group directly, and the harms in older adults are not quantified in the same study.
Sources used 4
-
A Randomized Trial of Colchicine for Acute Pericarditis
This study demonstrates that colchicine significantly reduces the rate of incessant or recurrent pericarditis when added to conventional anti-inflammatory therapy in patients experiencing their first episode of acute pericarditis.
DOI: 10.1056/nejmoa1208536 -
Does colchicine decrease the rate of recurrence of acute idiopathic pericarditis treated with glucocorticoids?
This study investigates the effect of colchicine on the recurrence rate of acute idiopathic pericarditis in patients treated with glucocorticoids, finding that colchicine does not reduce recurrence risk and may even increase it when combined with prednisone.
DOI: 10.1016/j.jjcc.2017.10.005 -
Acute recurrent pericarditis: from pathophysiology towards new treatment strategy
This article reviews the pathophysiology of acute recurrent pericarditis, highlighting innate immune activation via the inflammasome and IL-1, and surveys current and emerging treatments (NSAIDs, colchicine, corticosteroids, and IL-1 inhibitors) while outlining remaining challen…
DOI: 10.1136/heartjnl-2019-316481 -
Management of pericarditis
A comprehensive narrative review summarizing the etiologies, diagnostic workup, and guideline-based management of pericarditis, including NSAID and colchicine therapy, corticosteroid use, autoinflammatory/inflammatory approaches, imaging strategies, and interventional options fo…
DOI: 10.4081/itjm.2019.1153